602 related articles for article (PubMed ID: 36109793)
1. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
[TBL] [Abstract][Full Text] [Related]
2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
3. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
4. IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.
Zhao T; Jin F; Xiao D; Wang H; Huang C; Wang X; Gao S; Liu J; Yang S; Hao J
Theranostics; 2020; 10(9):4088-4100. PubMed ID: 32226541
[TBL] [Abstract][Full Text] [Related]
5. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
6. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
7. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
9. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Ma J; Weng L; Jia Y; Liu B; Wu S; Xue L; Yin X; Mao A; Wang Z; Shang M
J Cell Mol Med; 2020 Mar; 24(5):2917-2930. PubMed ID: 31989778
[TBL] [Abstract][Full Text] [Related]
10. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
12. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway.
Zhao F; Yang G; Qiu J; Liu Y; Tao J; Chen G; Su D; You L; Zheng L; Zhang T; Zhao Y
Mol Carcinog; 2022 Sep; 61(9):839-850. PubMed ID: 35785493
[TBL] [Abstract][Full Text] [Related]
13. Vav1-dependent Rac1 activation mediates hypoxia-induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF-1α expression.
Zhu C; Hu H; Ma Y; Xiong S; Zhu D
Cell Biol Int; 2023 Nov; 47(11):1835-1842. PubMed ID: 37545183
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
[TBL] [Abstract][Full Text] [Related]
15. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
16. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
18. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
Patzak MS; Kari V; Patil S; Hamdan FH; Goetze RG; Brunner M; Gaedcke J; Kitz J; Jodrell DI; Richards FM; Pilarsky C; Gruetzmann R; Rümmele P; Knösel T; Hessmann E; Ellenrieder V; Johnsen SA; Neesse A
EBioMedicine; 2019 Feb; 40():394-405. PubMed ID: 30709769
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer.
Wang Z; Qin J; Zhao J; Li J; Li D; Popp M; Popp F; Alakus H; Kong B; Dong Q; Nelson PJ; Zhao Y; Bruns CJ
Theranostics; 2020; 10(16):7178-7192. PubMed ID: 32641986
[TBL] [Abstract][Full Text] [Related]
20. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.
Liu K; Geng Y; Wang L; Xu H; Zou M; Li Y; Zhao Z; Chen T; Xu F; Sun L; Wu S; Gu Y
Mol Oncol; 2022 Aug; 16(16):3034-3051. PubMed ID: 35810469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
